Skip Ribbon Commands
Skip to main content
A- A A+

Find a Doctor

Dr Anand Jeyasekharan

Designations:
  • Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
  • Assistant Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
Qualifications:
MBBS (CMC Vellore, India), MRCP (UK), PhD (Cantab), FAMS (Medical Oncology)
Specialties:
Haematology, Medical Oncology
Special Interests:
Lymphomas, Rare Cancers, and Targeting Genomic Instability in Cancer

Biosketch

Dr Jeyasekharan obtained his undergraduate medical degree from Christian Medical College Vellore, India in 2003. He then received a Gates Cambridge Scholarship towards a PhD in Oncology (2008) at the University of Cambridge UK (Gonville and Caius College). Following a junior research fellowship in Cambridge (Wolfson), he joined the National University Hospital Singapore in 2010 to complete his training in Internal Medicine, and Medical Oncology (2016).

Dr. Jeyasekharan has a special interest in the treatment of lymphomas, as well as personalized therapy for rare and advanced cancers. He holds a joint appointment at the Cancer Science Institute, where runs a translational cancer research laboratory. His laboratory focuses on understanding defects in DNA repair in tumours, and how these impact the efficacy of chemotherapy/ immunotherapy. Dr. Jeyasekharan holds multiple internal and nationally funded grants to support his research, and is a platform lead for a national program on molecular diagnostics in cancer through the Singapore Translational Cancer Consortium.

Awards

  • 2021: Clinician Scientist Award Investigator, National Medical Research Council Awards
  • 2017: Transition Award, National Medical Research Council Awards

Journals & Publications

  1. Hoppe, M. M., P. Jaynes, J. D. Wardyn, S. S. Upadhyayula, T. Z. Tan, S. Lie, D. G. Z. Lim, B. N. K. Pang, S. Lim, J. P. S. Yeong, A. Karnezis, D. S. Chiu, S. Leung, D. G. Huntsman, A. S. Sedukhina, K. Sato, M. D. Topp, C. L. Scott, H. Choi, N. R. Patel, R. Brown, S. B. Kaye, J. J. Pitt, D. S. P. Tan and Jeyasekharan AD (2021). "Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer." EMBO Mol. Med. e13366.
  2. Ngoi, N., J. Lim, S. Ow, W. Y. Jen, M. Lee, W. Teo, J. Ho, R. Sundar, M. L. Tung, Y. M. Lee, E. Ngo, S. W. Lim, J. Ong, F. Lim, G. Bonney, B. Vellayappan, F. Ho, J. Tey, N. Chan, S. de Mel, M. Poon, S. Y. Lee, L. P. Koh, T. C. Liu, L. K. Tan, A. S. C. Wong, A. L. A. Wong, S. E. Lim, A. Yeoh, J. E. Wong, D. Tan, B. C. Goh, W. J. Chng, R. Soo, C. E. Chee, Y. L. Chee, S. C. Lee, Jeyasekharan AD for National University Cancer Institute (NCIS) (2020). "A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore." Ann. Oncol. 31(7): 840-843.
  3. de Mel S, M. B. M. Rashid, X. Y. Zhang, J. Goh, C. T. Lee, L. M. Poon, E. H. L. Chan, X. Liu, W. J. Chng, Y. L. Chee, J. Lee, Y. C. Yuen, J. Q. Lim, B. K. H. Chia, Y. Laurensia, D. Huang, W. L. Pang, D. M. Z. Cheah, E. K. Y. Wong, C. K. Ong, T. Tang, S. T. Lim, S. B. Ng, S. Y. Tan, H.-Y. Loi, L. K. Tan, E. K. Chow and Jeyasekharan AD (2020). "Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma." Blood Cancer J. 10(1): 9.
  4. Hong G, Fan S, Phyu T, Maheshwari P, Hoppe MM, Phuong HM, de Mel S, Poon M, Ng SB, Jeyasekharan AD. Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma. J. Vis. Exp. 2019 (143), e58711, doi:10.3791/58711.
  5. Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2018 Dec 21:101084. doi: 10.1016/j.redox.2018.101084. PMID: 30612957
  6. Oon, M. L., Hoppe MM, S. Fan, T. Phyu, Phuong HM, S.-Y. Tan, S. S.-S. Hue, S. Wang, L. M. Poon, H. L. E. Chan, J. Lee, Y. L. Chee, Chng WJ, S. de Mel, X. Liu, Jeyasekharan AD and S.-B. Ng* (Joint senior authorship) (2019). "The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma." Leuk. Lymphoma 60(13): 3214-3224
  7. Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for Homologous Recombination Deficiency in Cancer. J Natl Cancer Inst. 2018 July, 110(7):704-713; PMID:29788099.
  8. Tay SH, Wong AS, Jeyasekharan AD. A patient with pembrolizumab-induced fatal polymyositis. Eur J Cancer. 2018 Jan, 91:180-182; PMID:29329695.
  9. Ng SB, Fan S, Hoppe M, De Mel S, Jeyasekharan AD. Quantitative Analysis of a Multiplexed Immunofluorescence Panel in T-Cell Lymphoma. SLAS Technol 2017 Dec, PMID:29241019.
  10. Ng SB, Chung TH, Kato S, Nakamura S, Takahashi E, Ko YH, Khoury JD, Yin CC, Soong R, Jeyasekharan AD, Hoppe MM, Selvarajan V, Tan SY, Lim ST, Ong CK, Nairismägi ML, Maheshwari P, Choo SN, Fan S, Lee CK, Chuang SS, Chng WJ. EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes. Haematologica 2017 Nov 2, 180430; PMID:29097495.

Professional Memberships

  • ​Royal College of Physicians, London
  • Academy of Medicine, Singapore


 

Back to Top